Five Prime Therapeutics, Inc.

Bristol-myers Squibb Compnay

Luis Borges

Paul O Sheppard

Alan J Korman

Arvind Rajpal

Ginger Chao Rakestraw

Keith Sadoon Bahjat

Robert J Johnston

Andrew Rankin

Lin Hui Su

Guodong Chen

Richard Y Huang

David Bellovin

Ekaterina G Deyanova

Nels P Nielson

Kathy Miller

Andy X Deng

Maike Schmidt

Xiaodi Deng

Majid Ghoddusi

Charles Kaplan

Jason Robert Pinckney

Derrick Houser

Gloria Brattich

Felicia Kemp

David A Critton

Akbar Nayeem

Michael Quigley

Hadia Lemar

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

B7-H4 antibodies and methods of use thereof

Growing community of inventors

Houston, TX, United States of America

Luis Borges